Official Title
Expanded Access Treatment Protocol for R007 (Probucol) Tablets in Adults With Genetically-Confirmed Mitochondrial Disease and Chronic Kidney Disease (Intermediate-Size Patient Population)
Brief Summary

The purpose of this expanded access program is to enable access to R007 (probucol)tablets for the compassionate treatment of adults with mitochondrial disease who alsohave chronic kidney disease.

Detailed Description

The protocol for this expanded access program provides for the compassionate treatment
with R007 (probucol) tablets of adults who (i) have serious or life-threatening
mitochondrial disease and also have chronic kidney disease stages 3 or 4, (ii) do not
have access to a satisfactory alternative therapy to treat their condition, and (iii) are
not able to enroll in a clinical trial.

Available
Intermediate-size Population
Mitochondrial Disease
Chronic Kidney Disease

Drug: Probucol

Probucol 250 mg tablets orally up to a daily dose of 1,000 mg
Other Name: R007,Lorelco

Eligibility Criteria

Inclusion Criteria

A patient must meet all of the following criteria to be eligible:

1. Age 18 to 75 years inclusive;

2. Diagnosis of genetically-confirmed mitochondrial disease with a pathogenic mutation
or defect in their mitochondrial or nuclear DNA;

3. Diagnosis of chronic kidney disease stage 3 or stage 4;

4. Moderate or severe symptomatology of mitochondrial disease;

5. A sexually-active patient agrees to practice acceptable methods of contraception
throughout the protocol period;

6. The patient is not eligible for, or does not have access to, a clinical trial;

7. The patient (or guardian/legal representative) provides signed and dated informed
consent to be treated with probucol in accordance with the expanded access protocol.

Exclusion Criteria

A patient who meets any of the following criteria will not be eligible:

1. A known hypersensitivity or adverse reaction to probucol;

2. A medical condition or laboratory result that, in the opinion of the treating
physician, will interfere with the safe completion of the protocol;

3. An active fungal infection, acute blood, lung, or bladder infection, clinically
significant hepatic or renal dysfunction, and/or viral infection (past or present)
that, in the opinion of the treating physician, may have a clinically significant
effect on their treatment;

4. Taking an investigational drug other than probucol within one month prior to the
first dosing with probucol under the protocol;

5. A medical history or condition that increases the potential for QTc prolongation;

6. A female with a positive pregnancy test result or who is breastfeeding;

7. Has received or is receiving kidney dialysis;

8. Has received or is scheduled to receive an organ transplant;

9. Known or suspected active alcohol and/or substance abuse;

10. A history of or current suicidal ideation, behavior, and/or attempts; or

11. Is unable to swallow tablets or requires gastric feeding.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 75 Years
Countries
United States
Locations

The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States

Investigator: Zarazuela Zolkipli-Cunningham, MBChB
Contact: 267-426-4961
MMFP@chop.edu

Investigator: Zarazuela Zolkipli-Cunningham, MBChB

Contacts

Zarazuela Zolkiplki-Cunningham, MBChB
267-426-4961
MMFP@chop.edu

Sara Nguyen, MPH
267-426-1986
MMFP@CHOP.edu

Zarazuela Zolkipli-Cunningham, MBChB, Principal Investigator
Children's Hospital of Philadelphia

Children's Hospital of Philadelphia
NCT Number
Keywords
Mitochondrial Disease
Chronic kidney disease
Myopathy
Genetic disease
rare disease
Probucol
MeSH Terms
Kidney Diseases
Renal Insufficiency, Chronic
Mitochondrial Diseases
Probucol